What this study is
Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.
What's being tested
- TRPM8 Agonist
Intervention · DRUG
menthol gel 4-10%
- TRPV1 Agonist
Intervention · DRUG
camphor gel 5-20%
- TRPV4 Agonist
Intervention · DRUG
capsaicin gel 0.05-1%%
- TRPM8, TRPV4, TRPV1 Agonists
Intervention · DRUG
menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
- Vehicle gel
Intervention · OTHER
Inactive vehicle gel
Study details
- Official title
- Transient Receptor Potential Channels in Human Skin
- Sponsor
- Penn State University
- Conditions
- Aging
- Enrolling
- 45 people
- Starts
- 2024-07-17
- Est. completion
- 2027-12-31
- Design
- Single-blind, randomized, single group, Early Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 85 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- 18-85 years old.
- Women will not be pregnant and/or breastfeeding.
You can't join if
- Currently pregnant or breastfeeding
- Nicotine use (e.g., smoking, chewing tobacco etc.), quantified as more than 100 cigarettes or cigars in a lifetime)
- Known skin allergies or current rash, skin disease, disorders of pigmentation
- Diabetes
- Body mass index >35kg*m-2
- Using calcium channel blockers
- Raynaud's syndrome
- Allergy or hypersensitivity to menthol, camphor, capsaicin or adhesive
- Regular use (defined as greater than once a week) of topical analgesics that contain menthol, camphor or capsaicin
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openNoll Laboratory
University Park, Pennsylvania, United States
Study team
Sponsor
Penn State University
Study ID 24921
Principal investigator
Lacy Alexander, Ph.D.
Penn State University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.